Drug intelligence / Profile preview

SLS-002

Development stage: Phase 2
Lead developer: Seelos Therapeutics
Modality: Inhalation Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules
Administration: Intranasal

Overview

SLS-002 is an investigational intranasal formulation of racemic ketamine developed for the treatment of acute suicidal ideation and behavior (ASIB) in adults with major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). Racemic ketamine is a mixture of two enantiomers, esketamine and arketamine. The drug acts as a noncompetitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, which is believed to contribute to its rapid antidepressant effects. SLS-002 has demonstrated early and persistent reductions in symptoms of depression and suicidality in clinical trials. It is being developed by Seelos Therapeutics[1][3][4][6].

Other names: intranasal racemic ketamine

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on SLS-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SLS-002.

Explore the full profile